Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.37 |
| ▸ | RELA | Q04206 | 2/20 | 0.37 |
| ▸ | CTSK | P43235 | 9/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3105952 | 0.93 | CA1 (0.40) | CA12CA14CA1CA2CA7 | |
| SCHEMBL5877427 | 0.87 | CYP1A2 (0.50) | CA1CA2CA7NFKB1NFKB2 | |
| SCHEMBL79739 | 0.86 | CA1 (0.40) | CA12CA14CA1CA2CA7 | |
| SCHEMBL2461102 | 0.86 | CA1 (0.40) | CA12CA14CA1CA2CA7 | |
| SCHEMBL16592307 | 0.85 | CA12 (0.40) | CA12CA14CA1CA2CA7 | |
| SCHEMBL18082649 | 0.85 | CA12 (0.40) | CA12CA14CA1CA2CA7 | |
| SCHEMBL762738 | 0.84 | CA12 (0.41) | CA12CA14CA1CA2CA7 | |
| SCHEMBL7674937 | 0.84 | CYP2C9 (0.41) | CA12CA14CA1CA2CA7 | |
| SCHEMBL2707882 | 0.83 | SMN1; SMN2 (0.33) | CA12CA1CA2CYP2C19 | |
| SCHEMBL19456373 | 0.81 | CA1 (0.35) | CA12CA14CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 470 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110054574-B | Synthesis method of fluorenylmethyloxycarbonyl-2, 3-dehydro-valine | 上海吉奉生物科技有限公司 | 2021-08-20 | — | — | CN | claimed |
| US-20260108546-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4720067-A1 | BICYCLIC HETEROARYLAMIDES HAVING GPR68 MODULATING ACTIVITY | Recursion Pharmaceuticals, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260062412-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2026-03-05 | — | — | US | disclosed |
| EP-4688768-A1 | NOVEL METTL3 INHIBITORS AND USE THEREOF IN THERAPY | Novalix (FR) | 2026-02-11 | — | — | EP | disclosed |
| EP-3897833-B1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMA (US) | 2026-02-04 | — | — | EP | disclosed |
| US-12540132-B2 | Preparation of tetrahydroindazole derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-02-03 | — | — | US | disclosed |
| US-20260015337-A1 | COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION | TRAWSFYNYDD THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260008758-A1 | LINEAR DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED | 2026-01-08 | — | — | US | disclosed |
| US-7169927-B2 | Indole-amide derivatives and their use as glycogen phosphorylase inhibitors | ASTRAZENECA AB (SE) | 2007-01-30 | — | — | US | disclosed |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC | 2006-10-05 | — | — | US | disclosed |
| WO-2006099379-A2 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS | TRANSTECH PHARMA, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| EP-1675835-A1 | METHODS OF PREPARATION OF DEHYDRO-DIKETOPIPERAZINES IN LIQUID PHASE OR OF SOLID SUPPORTED PHASE | Couladouros, Elias Andrea (GR) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005123685-A1 | TETRAHYDROQUINOLONES AND AZA-ANALOGUES THEREOF FOR USE AS DPP-IV INHIBITORS IN THE TREATEMENT OF DIABETES | ASTRAZENECA AB (SE) | 2005-12-29 | — | — | WO | disclosed |
| US-20050137421-A1 | Method for making fluorine labled L-Dopa | CTI PET SYSTEMS, INC. | 2005-06-23 | — | — | US | disclosed |
| WO-2005003102-A1 | METHODS OF PREPARATION OF DEHYDRO-DIKETOPIPERAZINES IN LIQUID PHASE OR OF SOLID SUPPORTED PHASE | COULADOUROS ELIAS (GR) | 2005-01-13 | — | — | WO | disclosed |
| US-6080838-A | SYNTHETIC CONSTRUCT PREPARED TO HOLD TWO PEPTIDE HELICES IN TIGHT ARRANGEMENT TO MIMIC DNA BINDING CONFORMATION; FOR INVESSTIGATIONAL STUDIES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2000-06-27 | — | — | US | disclosed |
| EP-1003751-A1 | HYDROXAMIC ACID SUBSTITUTED FUSED HETEROCYCLIC METALLOPROTEINASE INHIBITORS | AMGEN INC. (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999006410-A1 | HYDROXAMIC ACID SUBSTITUTED FUSED HETEROCYCLIC METALLOPROTEINASE INHIBITORS | AMGEN INC. (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540132-B2 | Preparation of tetrahydroindazole derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors | DGAT2, DGAT1, ACAT2 | CA12 4646/4885CA14 4699/4885CA1 3797/4885 |
| US-20260062412-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | MYT1, NTMT1, MYL6 | CA12 1692/4885CA14 1464/4885CA1 1098/4885 |
| US-20260015337-A1 | COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION | ACE2, ACE, TMPRSS2 | CA12 1648/4885CA14 1155/4885CA1 2339/4885 |
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GPR119 | CA12 2000/4885CA14 1941/4885CA1 2934/4885 |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | BACE1, BACE2, APP | CA12 3221/4885CA14 2818/4885CA1 631/4885 |
| US-20050137421-A1 | Method for making fluorine labled L-Dopa | MAOB, DBH, MAOA | CA12 3281/4885CA14 3355/4885CA1 2902/4885 |
| US-20260108546-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GCGR | CA12 1388/4885CA14 1708/4885CA1 3414/4885 |
| US-20260008758-A1 | LINEAR DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF | DPP3, DPP7, DPP9 | CA12 716/4885CA14 632/4885CA1 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.